Nurix Therapeutics

NRIX · NASDAQ

$26.10+$1.17 (+4.69%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $24.93

Latest news

NewsOct 12, 4:09 PM ET
CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate
Press releaseOct 12, 4:05 PM ETGlobe Newswire
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
NewsOct 12, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today’s Session
NewsOct 8, 2:12 AM ETRishabh Mishra
Stock Market: Will S&P 500 Open Up or Down Today?
Press releaseSep 29, 7:00 AM ETGlobe Newswire
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Press releaseAug 4, 7:00 AM ETGlobe Newswire
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Press releaseAug 4, 1:00 AM ETGlobe Newswire
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NewsJul 21, 4:07 PM ET
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%
NewsJul 21, 4:06 PM ET
Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments
NewsJul 21, 4:03 PM ET
Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period
Press releaseJul 21, 4:01 PM ETGlobe Newswire
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Press releaseJul 9, 4:01 PM ETGlobe Newswire
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releaseJul 6, 11:19 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
NewsJun 25, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsJun 8, 9:26 AM ETVandana Singh
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
NewsApr 8, 7:11 AM ET
Earnings Scheduled For April 8, 2026
NewsMar 25, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsJan 29, 7:00 AM ET
What 11 Analyst Ratings Have To Say About Nurix Therapeutics
Press releaseJan 14, 10:52 AM ETPRNewswire
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Press releaseJan 12, 7:00 AM ETGlobe Newswire
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
NewsJan 8, 8:00 AM ET
What 18 Analyst Ratings Have To Say About Nurix Therapeutics
Press releaseDec 24, 6:00 AM ETGlobe Newswire
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
NewsDec 10, 10:01 AM ETAvi Kapoor
Exxon Mobil To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
NewsDec 8, 12:33 PM ETAvi Kapoor
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
NewsNov 4, 6:45 AM ET
13 Analysts Have This To Say About Nurix Therapeutics
Press releaseOct 17, 9:00 AM ETPRNewswire
Precision Oncology Approaches Drive $312B Market Transformation
NewsOct 10, 9:00 AM ET
Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views
NewsOct 10, 2:53 AM ETAvi Kapoor
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday
NewsJul 31, 5:00 PM ET
6 Analysts Assess Nurix Therapeutics: What You Need To Know
NewsJul 14, 5:00 PM ET
A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts
NewsApr 29, 4:00 PM ET
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views
NewsApr 2, 9:01 AM ET
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts
NewsMar 17, 5:00 PM ET
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock
NewsJan 29, 8:00 AM ET
8 Analysts Have This To Say About Nurix Therapeutics
NewsDec 6, 12:01 PM ET
Decoding 9 Analyst Evaluations For Nurix Therapeutics
NewsNov 6, 12:00 PM ET
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts
NewsOct 31, 3:23 PM ETChris Katje
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
NewsOct 11, 1:03 PM ET
Unveiling 6 Analyst Insights On Nurix Therapeutics
NewsOct 11, 8:40 AM ETAvi Kapoor
This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Press releaseSep 24, 9:15 AM ETPRNewswire
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
NewsSep 4, 3:01 PM ET
Analyst Ratings For Nurix Therapeutics
NewsAug 14, 7:43 AM ETAvi Kapoor
TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
NewsJul 31, 11:01 AM ET
Forecasting The Future: 13 Analyst Projections For Nurix Therapeutics
NewsJul 15, 11:00 AM ET
Analyst Scoreboard: 12 Ratings For Nurix Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

10 Health Care Stocks With Whale Alerts In Today’s Session

Stock Market: Will S&P 500 Open Up or Down Today?

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%

Nurix Therapeutics To Receive $700M In Funding As Part Of Collaboration Agreement With Roche, Up To $2.3B After Milestone Payments

Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

12 Health Care Stocks Moving In Thursday's Intraday Session

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Earnings Scheduled For April 8, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

What 11 Analyst Ratings Have To Say About Nurix Therapeutics

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

What 18 Analyst Ratings Have To Say About Nurix Therapeutics

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

Exxon Mobil To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday

13 Analysts Have This To Say About Nurix Therapeutics

Precision Oncology Approaches Drive $312B Market Transformation

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views

Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday

6 Analysts Assess Nurix Therapeutics: What You Need To Know

A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views

Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts

Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock

8 Analysts Have This To Say About Nurix Therapeutics

Decoding 9 Analyst Evaluations For Nurix Therapeutics

The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

Unveiling 6 Analyst Insights On Nurix Therapeutics

This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Analyst Ratings For Nurix Therapeutics

TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday

Forecasting The Future: 13 Analyst Projections For Nurix Therapeutics

Analyst Scoreboard: 12 Ratings For Nurix Therapeutics